Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement

This study has been completed.

Sponsor:

Collaborator:

CSL Behring

Information provided by (Responsible Party):

Andrej Petrov, University of Pittsburgh

ClinicalTrials.gov Identifier:

NCT01361178

First received: May 13, 2011

Last updated: February 1, 2017

Last verified: February 2017

History of Changes

Results First Received: February 1, 2017

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	Infections After Lung Transplant
Intervention:	Drug: SQ IVIG

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Transplant Patients Who do Not Receive SQ IVIG	Patients participating in the observational arm of the study who do not need to receive IgG replacement.
Transplant Patients Who Receive SQ IVIG	Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level. SQ IVIG: Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week

Description

Transplant Patients Who do Not Receive SQ IVIG

Patients participating in the observational arm of the study who do not need to receive IgG replacement.

Transplant Patients Who Receive SQ IVIG

Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.

SQ IVIG: Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week

Participant Flow: Overall Study

	Transplant Patients Who do Not Receive SQ IVIG	Transplant Patients Who Receive SQ IVIG
STARTED	122	11
COMPLETED	109	11
NOT COMPLETED	13	0
Death	13	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Transplant Patients Who do Not Receive SQ IVIG	Patients participating in the observational arm of the study who do not need to receive IgG replacement.
Transplant Patients Who Receive SQ IVIG	Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level. SQ IVIG: Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
Total	Total of all reporting groups

Description

Transplant Patients Who do Not Receive SQ IVIG

Patients participating in the observational arm of the study who do not need to receive IgG replacement.

Transplant Patients Who Receive SQ IVIG

Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.

SQ IVIG: Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week

Total

Total of all reporting groups

Baseline Measures

	Transplant Patients Who do Not Receive SQ IVIG	Transplant Patients Who Receive SQ IVIG	Total
Overall Participants Analyzed [Units: Participants]	122	11	133

Age [Units: Years] Median (Full Range)	62 (18 to 75)	52 (26 to 70)	61 (18 to 75)

Sex: Female, Male [Units: Participants] Count of Participants
Female	46 37.7%	5 45.5%	51 38.3%
Male	76 62.3%	6 54.5%	82 61.7%

Race (NIH/OMB) [Units: Participants] Count of Participants
American Indian or Alaska Native	0 0.0%	0 0.0%	0 0.0%
Asian	1 0.8%	0 0.0%	1 0.8%
Native Hawaiian or Other Pacific Islander	0 0.0%	0 0.0%	0 0.0%
Black or African American	8 6.6%	0 0.0%	8 6.0%
White	113 92.6%	11 100.0%	124 93.2%
More than one race	0 0.0%	0 0.0%	0 0.0%
Unknown or Not Reported	0 0.0%	0 0.0%	0 0.0%

Diagnosis [Units: Participants] Count of Participants
IPF	44	2	46
COPD	37	3	40
Cystic Fibrosis	10	3	13
Scleroderma	11	1	12
Sarcoidosis	3	1	4
Pulmonary Hypertension	3	0	3
Other	14	1	15

Induction Agent [Units: Participants] Count of Participants
Alemtuzamab	84	5	89
Basiliximab	38	6	44

Outcome Measures

1. Primary:

The Primary Outcome Will be the Total Number of Days With Pneumonia. [ Time Frame: Up to two years post-transplant ]

Show Outcome Measure 1

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:

Name/Title: Andrej Petrov, MD
Organization: University of Pittsburgh
phone: 412-648-6215
e-mail: petrovaa@upmc.edu

Responsible Party:	Andrej Petrov, University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT01361178 History of Changes
Other Study ID Numbers:	09090483
Study First Received:	May 13, 2011
Results First Received:	February 1, 2017
Last Updated:	February 1, 2017

To Top